FAB vs. APTA, EVG, OCTP, IXI, VAL, PYC, NFX, BSFA, ROQ, and GENF
Should you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include Aptamer Group (APTA), Evgen Pharma (EVG), Oxford Cannabinoid Technologies (OCTP), IXICO (IXI), ValiRx (VAL), Physiomics (PYC), Nuformix (NFX), BSF Enterprise (BSFA), Roquefort Therapeutics (ROQ), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.
Aptamer Group (LON:APTA) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
Aptamer Group has a net margin of 0.00% compared to Aptamer Group's net margin of -179.67%. Aptamer Group's return on equity of -140.93% beat Fusion Antibodies' return on equity.
Fusion Antibodies has higher revenue and earnings than Aptamer Group. Fusion Antibodies is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.
Fusion Antibodies received 54 more outperform votes than Aptamer Group when rated by MarketBeat users.
1.5% of Aptamer Group shares are owned by institutional investors. Comparatively, 24.4% of Fusion Antibodies shares are owned by institutional investors. 31.7% of Aptamer Group shares are owned by company insiders. Comparatively, 10.4% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.
Aptamer Group has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500. Comparatively, Fusion Antibodies has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Summary
Aptamer Group and Fusion Antibodies tied by winning 6 of the 12 factors compared between the two stocks.
Get Fusion Antibodies News Delivered to You Automatically
Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Antibodies Competitors List
Related Companies and Tools
